Vir hepatitis D drug succeeds in first pivotal study
Source ↗
👁 1
💬 0
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
Comments (0)